Philipp Mandel1,2, Clemens Rosenbaum1,2, Raisa S Pompe1, Thomas Steuber1, Georg Salomon1, Felix K Chun2, Markus Graefen1, Hartwig Huland1, Derya Tilki3,4. 1. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. 2. Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. 3. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. d.tilki@uke.de. 4. Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. d.tilki@uke.de.
Abstract
PURPOSE: This study aimed at analysing long-term oncologic outcomes in prostate cancer patients with limited nodal disease (1-2 positive lymph nodes) without adjuvant therapy after radical prostatectomy (RP). METHODS: We retrospectively analysed data of 209 pN1 patients who underwent RP between January 1998 and 2010 with one (160) or two (49) histologically proven positive lymph nodes (LNs) without adjuvant treatment. Biochemical recurrence-free survival, metastasis-free survival and cancer-specific survival (CSS) were reported. In multivariable regression analyses further prognosticators of oncologic outcome in these patients were analysed. RESULTS: Median follow-up was 60.2 months. There was no significant difference in oncologic outcome between patients with one and two positive LNs. 73.1% (76.7%) of patients with one (two) positive LNs had biochemical recurrence during the follow-up period, 20.0% (25.6%) developed metastasis and 8.1% (6.1%) died of their disease. The only factors significantly associated with oncologic outcome in multivariable analysis were Gleason score and pT-stage. CONCLUSIONS: Patients with limited nodal disease (1-2 positive LNs) without adjuvant therapy showed favourable CSS-rates above 94% after 5 years. A subgroup of these patients (37%) remained metastasis-free without need of salvage treatment.
PURPOSE: This study aimed at analysing long-term oncologic outcomes in prostate cancerpatients with limited nodal disease (1-2 positive lymph nodes) without adjuvant therapy after radical prostatectomy (RP). METHODS: We retrospectively analysed data of 209 pN1 patients who underwent RP between January 1998 and 2010 with one (160) or two (49) histologically proven positive lymph nodes (LNs) without adjuvant treatment. Biochemical recurrence-free survival, metastasis-free survival and cancer-specific survival (CSS) were reported. In multivariable regression analyses further prognosticators of oncologic outcome in these patients were analysed. RESULTS: Median follow-up was 60.2 months. There was no significant difference in oncologic outcome between patients with one and two positive LNs. 73.1% (76.7%) of patients with one (two) positive LNs had biochemical recurrence during the follow-up period, 20.0% (25.6%) developed metastasis and 8.1% (6.1%) died of their disease. The only factors significantly associated with oncologic outcome in multivariable analysis were Gleason score and pT-stage. CONCLUSIONS:Patients with limited nodal disease (1-2 positive LNs) without adjuvant therapy showed favourable CSS-rates above 94% after 5 years. A subgroup of these patients (37%) remained metastasis-free without need of salvage treatment.
Authors: Philippe E Spiess; Andrew K Lee; Joseph E Busby; Jennifer J Jordan; Mike Hernandez; Kristina Burt; Patricia Troncoso; Kelly W Merriman; Louis L Pisters Journal: BJU Int Date: 2006-11-28 Impact factor: 5.588
Authors: Trinity J Bivalacqua; Phillip M Pierorazio; Michael A Gorin; Mohamad E Allaf; H Ballentine Carter; Patrick C Walsh Journal: Urology Date: 2013-09 Impact factor: 2.649
Authors: Lars Budäus; Hendrik Isbarn; Thorsten Schlomm; Hans Heinzer; Alexander Haese; Thomas Steuber; Georg Salomon; Hartwig Huland; Markus Graefen Journal: Eur Urol Date: 2009-05-29 Impact factor: 20.096
Authors: Georgios Gakis; Stephen A Boorjian; Alberto Briganti; Steven Joniau; Guram Karazanashvili; R Jeffrey Karnes; Agostino Mattei; Shahrokh F Shariat; Arnulf Stenzl; Manfred Wirth; Christian G Stief Journal: Eur Urol Date: 2013-05-22 Impact factor: 20.096
Authors: Guido Sauter; Stefan Steurer; Till Sebastian Clauditz; Till Krech; Corinna Wittmer; Florian Lutz; Maximilian Lennartz; Tim Janssen; Nayira Hakimi; Ronald Simon; Mareike von Petersdorff-Campen; Frank Jacobsen; Katharina von Loga; Waldemar Wilczak; Sarah Minner; Maria Christina Tsourlakis; Viktoria Chirico; Alexander Haese; Hans Heinzer; Burkhard Beyer; Markus Graefen; Uwe Michl; Georg Salomon; Thomas Steuber; Lars Henrik Budäus; Elena Hekeler; Julia Malsy-Mink; Sven Kutzera; Christoph Fraune; Cosima Göbel; Hartwig Huland; Thorsten Schlomm Journal: Eur Urol Date: 2015-11-02 Impact factor: 20.096
Authors: Esmée C A van der Sar; Willem R Keusters; Ludwike W M van Kalmthout; Arthur J A T Braat; Bart de Keizer; Geert W J Frederix; Anko Kooistra; Jules Lavalaye; Marnix G E H Lam; Harm H E van Melick Journal: Insights Imaging Date: 2022-08-13
Authors: Thijs H Huits; Henk B Luiting; Henk G van der Poel; Rohan Nandurkar; Maarten Donswijk; Eva Schaake; Wouter Vogel; Monique J Roobol; Esther Wit; Phillip Stricker; Louise Emmett; Pim J van Leeuwen Journal: BJU Int Date: 2020-04-23 Impact factor: 5.588